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A 28-year-old gravida 2, para 1 female presented
at 10 weeks’ gestation to the burn unit with 30% body
surface area of full-thickness erosions and flaccid
bullae on the face, trunk, extremities, and mucosal
surfaces including the eyes, mouth, and vagina
(Fig 1, A and B). Her symptoms began 2 days prior
with stinging and swelling of the eyes and lips that
quickly progressed to generalized erythema and
subsequent blister formation and desquamation.
Associated symptoms included headache, malaise,
and fever up to 39.48C.
Skin biopsy found vacuolar alteration and
necrotic keratinocytes along the dermal-epidermal
junction and sparse lymphocytic infiltrate, confirm-
ing the suspected diagnosis of toxic epidermal
necrolysis (TEN) (Fig 1, C ).
Her medical history was significant for culture-
positive group A b-hemolytic streptococcal pharyn-
gitis that was treatedwith a 10-day course of penicillin
V potassium (500 mg twice daily) approximately
1 month before to the onset of her rash. At the time
of presentation, she was taking a multivitamin and
fish oil. Her laboratory serology results were negative
for herpes simplex virus, human immunodeficiency
virus, and mycoplasma pneumonia. Although her
symptoms were potentially attributed to penicillin, it
is unusual for TEN to occur 4 weeks after discontin-
uation of a medication with a short half-life. Thus, an
altered immunologic state owing to pregnancy wasthe Department of Dermatology, University of California,
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m.also considered as a potential trigger for her Stevens-
Johnson syndrome (SJS)/TEN.1
Upon admission, she received a 1-time administra-
tion of methylprednisolone (125 mg) and intravenous
immunoglobulin (1 mg/kg). Her severity-of-illness
score for toxic epidermal necrolysis (SCORTEN)-
based mortality risk was 3.2% (SCORTEN: 1 for
[10% detached or compromised body surface), and
further treatment consisted of supportive therapywith
fluid resuscitation, opioid pain control, and topical
wound carewith bacitracin ointment.On the third day
of hospitalization, the ophthalmology department
transplanted amniotic membranes to prevent scarring
of the ocular surfaces.
One week after admission, she was noted to
have extensive desquamation and erosions of the
perineum. Two weeks after admission, she was
complaining of increased perineal pain and burning
sensation. Pelvic examination found horizontal
perineal strictures, fusion of the labia majora, minora,
and clitoral hood, and a complete circumferential
transverse vaginal stricture 2 cm from the introitusJAAD Case Reports 2016;2:202-5.
2352-5126
 2016 by the American Academy of Dermatology, Inc. Published
by Elsevier, Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
http://dx.doi.org/10.1016/j.jdcr.2016.03.006
Fig 1. A and B, A 28-year-old woman on presentation with greater than 30% body surface area
of full-thickness erosions and flaccid bullae on the face, trunk, extremities, and mucosal
surfaces including the eyes, mouth, and groin. C, Hematoxylin-eosinestained biopsy from the
lower abdomen with vacuolar interface dermatitis, prominent keratinocyte necrosis, and
preservation of the cornified layer consistent with TEN.
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nations (Fig 2, A and B).
To prevent complete fusion of the vagina, vaginal
packing and dilators were commenced with zinc
oxide application to erosions in the perineum. She
had significant pain with dilator insertion that was
improved with topical lidocaine jelly. Because of
clitoral hood involvement and concern for adhesion
formation near the urethra, her Foley catheter
remained in place until the perineal area was fully
re-epithelialized.
She was discharged from the hospital after
4 weeks of supportive therapy. Additional sequelae
noted after discharge included progressive shortness
of breath with obstructive lung disease, dysphagia
with esophageal stenosis, and trichiasis with
associated epiphora. Her pulmonary symptoms
gradually improved with inhaled corticosteroids.
She continued to have perineal discomfort and
used vaginal dilators 2 times daily as tolerated.Her pregnancy progressed without fetal com-
plications and she delivered a healthy boy by
cesarean section at 39 weeks’ gestation. Her intra-
partum vaginal examination found a foreshortened
vagina approximately 2 cm from the introitus,
similar to an imperforate hymen. A Hagar dilator
was inserted into the vagina, and the adhesions
were lysed.
She discontinued the use of vaginal dilators
1 week postpartum and recurrent symptomatic
vaginal stenosis and persistent vaginal discharge
developed. She has since undergone several
procedures including blunt dissection and surgical
excision of adhesions. At 4 months postpartum,
current management consists of continuous intra-
vaginal Foley catheterization to maintain patency
of the vaginal opening, nightly use of a vaginal
stent with estrogen cream, and daily place-
ment of a vaginal dilator with lidocaine jelly as
tolerated.
Fig 2. A and B, Two weeks after admission, the patient had horizontal perineal strictures,
agglutination of the labia and clitoral hood, and a complete circumferential transverse vaginal
stricture 2 cm from the introitus.
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SJS and TEN are overlapping cutaneous drug
reactions differing in extent of body surface area of
epidermal detachment. The clinical presentation is
characterized by potentially fatal mucocutaneous
erythema, tenderness, and exfoliation caused by a
dermal-epidermal interface dermatitis with resulting
apoptosis of keratinocytes. Erythema of the oral,
ocular, and genital mucosa is present in greater than
90% of cases. In one retrospective case series of
female TEN patients, 70% of women had vulvovagi-
nal lesions ranging from superficial vulvar erosions
to extensive vaginitis with ulceration and bullae
formation. Up to 28% of those women suffered
from long-term symptomatic sequelae of the lower
genital tract including burning sensation, dyspareu-
nia, and postcoital bleeding resulting from varying
degrees of vaginal adhesions and stenosis.2 Pediatric
cases of SJS/TEN have also been reported in which
patients likely had severe vulvar scarring and labial
agglutination early in the course of recovery.3
However, gynecologic sequelae of SJS/TEN are often
not detected until after the acute phase of disease
has ended, thus, limiting treatment options of
complications to primarily surgical interventions.3
The mechanism for mucosal scarring is likely related
to denuded surfaces adhering during the healingphase, resulting in loss of normal vaginal structure
and formation of scars. Thus, there is potential for
improvement with early intervention. Importantly,
scars can continue to mature for up to a year after
injury,4 so a successful treatment plan should include
long-term follow-up and longitudinal management
strategies.
Several measures have been proposed to protect
vaginal function and prevent adhesion formation.
Given their documented success in other inflamma-
tory vaginal disorders (eg, erosive lichen planus and
Sj€ogren’s syndrome), prophylactic vaginal dilation
and topical corticosteroids have been promoted as
first-line therapy at time of initial presentation and
then daily until complete re-epithelialization.5,6
Administration of topical corticosteroids in ophthal-
mology has shown a decrease in the incidence of
ocular cicatrization and vision loss.7 Topical
corticosteroids have not been prospectively studied
specifically for mucosal involvement of the genital
tract in SJS/TEN; however, there is a current ongoing
randomized, controlled clinical trial evaluating the
safety and efficacy of topical clobetasol 0.05%
ointment for cutaneous involvement.8
In our experience, once-formed, significant
vulvovaginal scarring and stenosis are difficult to
manage, even with appropriate surgical intervention.
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of a vaginal dilator may be required to prevent
recurrences. Given the high morbidity associated
with gynecologic adhesions and the relatively low
risk of complications associated with topical steroid
application and mechanical vaginal dilator insertion,
we recommend early initiation of these interventions.
Gynecologic examination of all individuals with SJS/
TEN, including the pediatric population, is imperative
to facilitate early identification of genital ulcerations
and adhesions. Thismay require a pelvic examination
under anesthesia, which would also facilitate imme-
diate adhesiolysis. Specifically, if genital mucosal
exfoliation is evident, we recommend twice-daily
application of a high potency corticosteroid ointment
to the perineum externally followed by petroleum
gauze to prevent contact between adjacent eroded
mucosal surfaces. In addition, soft silicone vaginal
molds (ie, Milex dilator) or inflatable vaginal dilators
coated with high-potency corticosteroids can be
inserted daily for up to 24 hours to prevent fibrous
band formation until complete re-epithelialization of
ulcerated surfaces.6
The morbidity associated with TEN-associated gy-
necologic scarring is extreme and may include diffi-
culties with menstruation, intercourse, and labor later
in life.4 A multidisciplinary cooperative effort focused
on preventative measures used early in the acutephase of SJS/TEN by dermatologic, gynecologic,
ophthalmologic, and burn unit staff will likely yield
the best treatment outcomes in female patients with
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